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THIS ISSUE’S AUTHORS
SCOTT E. BOWEN, Ph.D., is an associ-
ate professor and area chair of the Behav-
ioral and Cognitive Neuroscience Program 
within the Department of Psychology at 
Wayne State University (WSU). He is also 
an associate professor in WSU’s Depart-
ment of Obstetrics and Gynecology. His 
preclinical research is focused on behavioral 
pharmacology, behavioral toxicology, and 
neurobehavioral teratology. He investigates 
the acute and chronic behavioral effects of 
abused drugs, with a particular interest in   
volatile substances. Dr. Bowen’s research 
also targets the development of a rodent 
model of prenatal misuse of volatile organic 
solvents (e.g., toluene). 
C. HENDRICKS BROWN, Ph.D., is a 
professor in the Department of Epidemiology 
and Public Health at the University of Miami 
Miller School of Medicine. Since 1985, he has 
received support from the National Institute 
of Mental Health and, more recently, from 
the NIDA to develop statistical methods for 
the design and analysis of preventive trials. 
As director of the Prevention Science and 
Methodology Group, Dr. Brown leads a net-
work of methodologists who are working on 
the design of preventive field trials and their 
analysis, particularly with advanced tech-
niques for growth analysis and for operating 
with missing data. 
MANORANJAN S. D’SOUZA, M.D., 
Ph.D., is a senior research fellow in the 
laboratory of Dr. Athina Markou at the 
University of California, San Diego School 
of Medicine. Dr. D’Souza’s research focuses 
on understanding the neurobiology of nico-
tine dependence. In 2010, he received a fel-
lowship from the Tobacco-Related Disease 
Research Program of the State of Califor-
nia to identify glutamatergic mechanisms 
involved in the extinction and reinstatement 
of nicotine-seeking behavior. 
ERIC GARLAND, Ph.D., L.C.S.W., is 
an assistant professor at the Florida State 
University College of Social Work and a 
research scholar of the Trinity Institute for 
the Addictions. As a post-doctoral fellow at 
the University of North Carolina at Cha-
pel Hill School of Medicine, he conducted 
a randomized controlled pilot trial of a 
mindfulness-oriented recovery enhancement 
intervention for alcohol-dependent adults. 
Informed by years of clinical experience as 
a licensed psychotherapist, Dr. Garland’s 
translational research agenda involves the 
development and testing of interventions 
that target the cognitive, affective, and psy-
chophysiological mechanisms implicated in 
addictive disorders. 
MATTHEW O.HOWARD, Ph.D., 
is a professor at the University of North 
Carolina at Chapel Hill (UNC) School of 
Social Work and a research fellow at UNC’s 
Cecil G. Sheps Center for Health Services 
Research. He has authored or coauthored 
168 journal articles and has served as an edi-
tor, editorial board member, and reviewer 
for numerous journals and publishers. He 
is currently editor-in-chief of Social Work 
Research. Dr. Howard’s research interests 
include inhalant use disorders, substance 
abuse and psychopathy among juvenile 
offenders, psychiatric disorders among inhal-
ant users, and integration of evidence-based 
practices.
SHEPPARD G. KELLAM, M.D., is profes-
sor emeritus and former chair of the Depart-
ment of Mental Health at the Johns Hopkins 
Bloomberg School of Public Health. Since 
1964, Dr. Kellam has designed, led, and 
collaborated in clinical and preventive trials 
conducted by interdisciplinary teams.  His 
work in prevention research has contributed 
basic concepts such as the developmental 
epidemiological prevention research strategy 
that has become a major focus of preven-
tion research and is now playing a role in 
the transition from research to practice.  He 
was the first president elected by the full 
membership of the Society for Prevention 
Research.
ADELAIDE M. LANG, Ph.D., is a 
research project coordinator at Case West-
ern Reserve University’s Mandel School 
of Applied Social Sciences. Dr. Lang is a 
licensed clinical psychologist with over 20 
years of experience working with children 
and families from high-risk populations.   
She has been a research staff member on 
Dr. Sonia Minnes’ longitudinal study of 
prenatal cocaine exposure since 2003.
ALEXANDRE B. LAUDET, Ph.D., is 
director of the Center for the Study of 
Addictions and Recovery at the National 
Development and Research Institutes, 
Inc. Her research focuses on elucidat-
ing patterns, processes, and psychosocial 
determinants of remission from substance 
use disorders, with the goal of informing 
service development and policy to create 
opportunities for long-term recovery and 
improved quality of life for people with these 
disorders. She serves on the editorial board 
of the Journal of Substance Abuse Treatment 
and of Substance Use & Misuse and provides 
consultancy to government agencies.
AMELIA MACKENZIE, B.S., is a Master 
of Science student at the Johns Hopkins 
Bloomberg School of Public Health and a 
research assistant at the University of Mary-
land, School of Medicine, working in the 
fields of prevention science and reproductive 
health. Ms. Mackenzie has held leadership 
positions in the Women’s Health Action 
Group and Health Leads. She is a member 
of the Delta Omega Honorary Society in 
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ATHINA MARKOU, Ph.D., a professor in 
the Department of Psychiatry, University of 
California, San Diego, has published about 
150 journal articles and 40 book chapters. 
She is senior editor of Neuropharmacology 
and associate editor of Neuroscience & Biobe-
havioral Reviews. She received the Efron 
Award from the American College of Neu-
ropsychopharmacology. Dr. Markou has 
been the principal investigator or director of 
several National Institutes of Health (NIH) 
grants, including a cooperative agreement 
on the discovery of GABAergic treatments 
for nicotine dependence. She has consulted 
with the United Nations, the World Health 
Organization, the NIH, and pharmaceutical 
companies. 
SONIA MINNES, Ph.D., is an assistant 
professor of social work at the Mandel 
School of Applied Social Sciences, Case 
Western Reserve University.  Her research 
interests are child development and the pre- 
and postnatal factors that affect cognitive 
and mental health outcomes.  Dr. Minnes 
is the principal investigator of a longitudinal 
study of prenatal cocaine exposure funded 
by NIDA. This study has followed a group 
of over 400 caregiver/child pairs since the 
children were born during 1994–1996. Dr. 
Minnes is currently assessing the study sub-
jects as adolescents, evaluating their behav-
ioral risk taking, initiation of substance use, 
development of mental health problems, 
and academic achievements.
BRIAN PERRON, Ph.D., is an associate 
professor of social work at the University of 
Michigan.  His research focuses on mental 
disorders and addiction, emphasizing ser-
vices, clinical epidemiology, and psycho-
metrics. He has active National Institutes 
of Health grants as a principal investigator, 
in addition to other projects funded by the 
State of Michigan and various centers of the 
University of Michigan.  One of Dr. Per-
ron’s current projects involves examining 
the diagnostic formulation of inhalant use 
disorders, with an emphasis on withdrawal.  
He is also involved in the education of social 
workers and social work researchers at both 
the master’s and doctoral levels.    
HANNO PETRAS, Ph.D., is the associate 
director of research and development at JBS 
International, Inc., a company focused on 
understanding the health, social, and educa-
tional needs of people across their lifespan. 
His research interests and expertise are in 
the development of antisocial behavior, the 
design and evaluation of preventive inter-
ventions, and the appropriate application 
of statistical methods using latent variables. 
Dr. Petras serves on the board of directors 
for the Society for Prevention Research. He 
serves as the consulting editor for Prevention 
Science and is currently editing a book series 
that focuses on defining prevention science. 
JEANNE PODUSKA, Sc.D., is a manag-
ing researcher at the American Institutes 
for Research and director of the Center for 
Integrating Education and Prevention in 
Schools. She has the appointment of associ-
ate in the Johns Hopkins University Depart-
ment of Mental Health. Dr. Poduska has 
worked at the intersection of public health, 
prevention, and education for the past 20 
years, partnering with schools and districts 
to develop and test interventions aimed at 
early risk factors.  Her recent work bridges 
effectiveness research and type 2 transla-
tional research with the goal of moving 
evidence-based programs into practice with 
high-quality fidelity. 
ALEXANDRA E. SHIELDS, Ph.D., is 
director of the Harvard/MGH Center on 
Genomics, Vulnerable Populations, and 
Health Disparities; associate professor of 
medicine at Harvard Medical School; asso-
ciate faculty in molecular and population 
genetics at the Broad Institute; and codirec-
tor of the Harvard Catalyst Health Dispari-
ties Research Program. Dr. Shields’ work 
addresses the challenges of clinical integra-
tion of new genomic medicine and technolo-
gies into clinical practice, with a particular 
focus on the impact of these changes on 
minority and underserved populations.   
She also studies important ethical aspects 
of genomics research design, including the 
use of race constructs and the inclusion of 
environmental measures most important 
to understanding health disparities in gene-
environment interaction studies. 
LYNN T. SINGER, Ph.D., is a professor 
of environmental health sciences, pediatrics, 
and psychiatry at Case Western Reserve Uni-
versity. She has directed numerous research 
programs, including a 19-year study of high-
risk preterm infants, longitudinal studies 
of drug-exposed infants in Cleveland and 
London, and a National Science Foundation 
program to enhance the careers of women 
faculty in science and engineering. She has 
edited two books and has authored more 
than 125 articles in the medical and psycho-
logical literature. Dr. Singer serves on the 
governing council of the Neurobehavioral 
Teratology Society and on a committee of 
the National Institutes of Health Center for 
Scientific Review.
MICHAEL G. VAUGHN, Ph.D., is an 
associate professor in the School of Social 
Work at Saint Louis University (SLU); he 
also holds appointments in SLU’s Depart-
ment of Public Policy Studies and in the 
Department of Community Health, School 
of Public Health. He has published more 
than 120 peer-reviewed articles and 25 book 
chapters. Dr. Vaughn’s research interests 
include adolescent drug use and abuse in 
relation to antisocial behavior over the life 
course.  Current projects include a cell-to-
society approach to the study of human 
behavior, drug use, and gun carrying and 
drug use epidemiology of criminal jus-
tice populations. 
WEI WANG, Ph.D., is an assistant pro-
fessor of biostatistics at the University of 
South Florida (USF). He has been the lead-
ing statistician in multiple prevention tri-
als, including classroom and family-based THIS ISSUE’S AUTHORS • 87
programs focused on reducing substance use 
and increasing academic performance. Dr. 
Wang has been a long-term member of the 
Prevention Science & Methodology Group, 
and he currently serves as the USF principal 
investigator for three federally funded grants.
HOLLY C. WILCOX, Ph.D., has a joint 
faculty appointment as an assistant professor 
in the Johns Hopkins School of Medicine 
Department of Psychiatry as well as the 
School of Public Health Department of 
Mental Health. Dr. Wilcox is a psychiat-
ric epidemiologist with a primary interest 
in the etiology and prevention of suicidal 
behaviors among young people. She is cur-
rently involved in a study of the etiology 
and pathways to suicide attempts among 
two cohorts of first-graders in Baltimore 
who participated in an intervention trial 
and were followed into adulthood. She 
also leads a study of early trauma exposure, 
hypothalamic-pituitary-adrenal axis func-
tion, and risk for suicide attempts among 
young people at familial risk for recurrent 
early-onset depression and is the Johns Hop-
kins principal investigator of a multisite 
genetic study of young people at risk for 
bipolar disorder.
RICK A. BEVINS, Ph.D., is a professor and 
vice chair of psychology at the University 
of Nebraska–Lincoln. His research focuses 
on the use of animal models to elucidate 
neuropharmacological and behavioral fac-
tors involved in the etiology of drug abuse. 
He has authored or coauthored more than 
100 articles, is an editor for the Journal of 
the Experimental Analysis of Behavior, and 
serves on the editorial advisory board of ACS 
Chemical Neuroscience.
MARGARET S. CHISOLM, M.D., is 
an assistant professor of psychiatry and 
behavioral sciences at The Johns Hopkins 
University and a psychiatrist at the Center 
for Addiction and Pregnancy at the Johns 
Hopkins Bayview Medical Center. Her pri-
mary research interest is the relationship 
between cigarette smoking, depression, and 
neonatal outcomes in drug-dependent preg-
nant patients. Dr. Chisolm is currently the 
primary investigator for a NIDA-supported 
study on pregnancy and drug abuse.
VICTORIA H. COLEMAN-COWGER, 
Ph.D., is a research scientist for Chestnut 
Health Systems, a mental health and sub-
stance abuse treatment provider in Bloom-
ington, Illinois. Her research focuses on 
smoking cessation and relapse prevention 
during pregnancy and postpartum. As an 
early-career investigator, Dr. Coleman-Cow-
ger has published empirical papers in the 
areas of substance abuse, smoking cessation 
during pregnancy, telephone counseling, 
mental health, and women’s health.
DANNY H. HALL, Ph.D., is coordina-
tor of the Intensive Outpatient Program 
at the John D. Dingell VA Medical Cen-
ter in Detroit, Michigan. He is currently 
working on effectiveness research and his 
supervisory interests include disseminat-
ing research-based treatments for addic-
tion and co-occurring disorders. Dr. Hall 
won an Early Career Investigator Awards at 
the American Psychological Association’s 
conference in 2005. He has also published 
articles concerning addiction treatment and 
training.
PAUL KENNY, Ph.D., is an associate pro-
fessor in the Department of Molecular Ther-
apeutics at The Scripps Research Institute. 
He also has a joint faculty appointment in 
the Kellogg School of Science and Technol-
ogy. Dr. Kenny’s research focuses on under-
standing the neurobiological mechanisms of 
drug addiction, obesity, and schizophrenia, 
with an emphasis on the role of nicotinic 
acetylcholine receptors in these processes. 
Dr. Kenny is a member of the Board of Sci-
entific Counselors for the NIDA Intramural 
Research Program. 
JED E. ROSE, Ph.D., is director of the 
Duke Center for Nicotine and Smoking 
Cessation Research and medical research 
professor in the Department of Psychiatry 
at Duke University Medical Center. Dr. 
Rose led the initial studies of transdermal 
nicotine administration, which helped pave 
the way for the development of commercial 
nicotine skin patches as a smoking cessation 
treatment. His current research uses brain 
imaging methodologies to identify brain 
substrates underlying craving and addiction. 
DAVE ROSS, Ph.D., is the clinical director 
of Behavioral Healthcare Services for Catho-
lic Charities CYO in the San Francisco Bay 
Area.  In addition to directing community-
based mental health and substance abuse 
programs, Dr. Ross maintains a private 
practice.  In his 35-year career, he has been 
clinical director for hospital-based chemi-
cal dependency programs and has trained 
interns to provide psychotherapy.
LUCY ZAMMARELLI, M.A., NCAC II, 
CADC III, is the clinical director at Wil-
lamette Family, Inc., a behavioral health 
care organization providing residential and 
outpatient services at six clinics in Eugene, 
Oregon. She serves on the National Child 
Traumatic Stress Network Steering Com-
mittee, where she co-chairs the Trauma 
and Substance Abuse Subcommittee. She 
also teaches in the University of Oregon’s 
Substance Abuse Prevention Program, with 
a focus on trauma treatment and issues per-
taining to families, veterans, and women.
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